# Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

> **NCT02255968** · PHASE1 · TERMINATED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** EDP-788
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02255968
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02255968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02255968, "Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02255968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*